comparemela.com

Nxc 201 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NXC-201 Receives Orphan Drug Designation in European Union for Multiple Myeloma

The CAR T-cell therapy NXC-201 has received orphan drug designation by the European Commission for patients with multiple myeloma.

Ilya rachmanGabriel morrisDrug administrationImmix biopharma incEuropean unionInternational myeloma society annual meetingNexcella incInternational myeloma working group uniform response criteriaEuropean commissionImmix biopharmaInternational myeloma society annualSingle dayAnnual meetingMyeloma society annual meetingNxc 201 receives orphan drug designationNxc 201

NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis

Faculty offer insights on the NEXICART-1 phase 1 clinical trial investigating the safety and efficacy of NXC-201 in patients with AL amyloidosis and discuss potential clinical implications on the study’s findings.

United statesVaishali sanchorawalaHeather landauJeffrey zonderPeer exchangeAmerican society of hematologyAmerican societyLight chain amyloidosisAl amyloidosisAffirm alNexicart 1Amyloid depositsCd 38 directed monoclonal antibodiesCardiac involvementMayo cardiac stagingStem cell transplant

Looking Ahead: Future Perspectives on AL Amyloidosis

Heather Landau, MD, invites panelists to provide their insights on the future outlook for the treatment of AL amyloidosis.

Vaishali sanchorawalaJeffrey zonderHeather landauPeer exchangeLight chain amyloidosisAl amyloidosisAffirm alNexicart 1Amyloid depositsCd 38 directed monoclonal antibodiesCardiac involvementMayo cardiac stagingStem cell transplantDuration of therapyUnmet needsManaging al amyloidosis

European Commission Grants Orphan Drug Designation to NXC-201 for AL Amyloidosis

NXC-201 has received orphan drug designation from the European Commission for use in patients with amyloid light-chain amyloidosis.

Ilya rachmanGabriel morrisEuropean commissionEuropean unionNexcella incDrug administrationInternational myeloma society annual meetingYork heart associationImmix biopharma incMyeloma society annual meetingImmix biopharmaMayo amyloidosisSingle dayOrphan drug designationNxc 201Al amyloidosis

Expert Insights on Pooled Safety Data from the PRONTO and VITAL trials

Vaishali Sanchorawala, MD, provides insights on the pooled safety analysis of data from phase 1 to 3 trials, including PRONTO and VITAL, which investigated the use of birtamimab in patients with light chain (AL) amyloidosis.

United statesVaishali sanchorawalaHeather landauJeffrey zonderPeer exchangeAmerican society of hematologyAmerican societyLight chain amyloidosisAl amyloidosisAffirm alNexicart 1Amyloid depositsCd 38 directed monoclonal antibodiesCardiac involvementMayo cardiac stagingStem cell transplant

vimarsana © 2020. All Rights Reserved.